What were Lincoln Pharmaceuticals Ltd's latest quarterly results?
Lincoln Pharmaceuticals Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: 0.0%
- Revenue Growth YoY: +11.3%
- Operating Margin: 13.0%
Lincoln Pharmaceuticals Ltd: Stock Analysis & Fundamentals
Updated this weekLincoln Pharmaceuticals Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 13.8. ROE: 12.3%. This stock is not currently in the Nifty 500 momentum outperformers list.
Lincoln Pharmaceuticals Ltd Key Facts
What's Happening
💪Debt reduced 100% YoY — balance sheet strengthening
Key Numbers
Current Price
₹604
Dividend Yield
0.30%
Market Cap
1.2K Cr
Valuation
N/AOther Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Lincoln Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Lincoln Pharmaceuticals Ltd's current PE ratio?
Lincoln Pharmaceuticals Ltd's current PE ratio is 13.8x.
- Current PE: 13.8x
- Market Cap: 1.2K Cr
- Dividend Yield: 0.30%
What is Lincoln Pharmaceuticals Ltd's price-to-book ratio?
Lincoln Pharmaceuticals Ltd's price-to-book ratio is 1.6x.
- Price-to-Book (P/B): 1.6x
- Book Value per Share: ₹378
- Current Price: ₹604
Is Lincoln Pharmaceuticals Ltd a fundamentally strong company?
Lincoln Pharmaceuticals Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 16.0%
Is Lincoln Pharmaceuticals Ltd debt free?
Lincoln Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹4 Cr
What is Lincoln Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Lincoln Pharmaceuticals Ltd's return ratios over recent years
- FY2024: ROCE 22.0%
- FY2025: ROCE 17.0%
- FY2026: ROCE 16.0%
Is Lincoln Pharmaceuticals Ltd's cash flow positive?
Lincoln Pharmaceuticals Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹106 Cr
- Free Cash Flow (FCF): ₹8 Cr
- CFO/PAT Ratio: 120% (strong cash conversion)
What is Lincoln Pharmaceuticals Ltd's dividend yield?
Lincoln Pharmaceuticals Ltd's current dividend yield is 0.30%.
- Dividend Yield: 0.30%
- Current Price: ₹604
Who holds Lincoln Pharmaceuticals Ltd shares — promoters, FII, DII?
Lincoln Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 49.8%
- FII (Foreign): 5.2%
- DII (Domestic): 1.1%
- Public: 43.9%
Is promoter holding increasing or decreasing in Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 49.8% (Mar 2026)
- Previous Quarter: 49.8% (Dec 2025)
- Change: 0.00% (stable)
Is Lincoln Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Lincoln Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Lincoln Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Lincoln Pharmaceuticals Ltd may be worth studying
- Cash flow is positive — CFO ₹106 Cr
What is the investment thesis for Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd investment thesis summary:
What is the future outlook for Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.